VERRICA ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Verrica Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm
Verrica Pharmaceuticals Inc. (VRCA)
Last verrica pharmaceuticals inc. earnings: 3/13 07:00 am
Check Earnings Report
Company Research
Source: Business Wire
NEW YORK--(BUSINESS WIRE)--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, announces that a class action lawsuit has been filed in the United States District Court for the Eastern District of Pennsylvania on behalf of investors that purchased Verrica Pharmaceuticals, Inc. (NASDAQ: VRCA) securities between September 16, 2019 and June 29, 2020 (the “Class Period”). Investors have until September 14, 2020 to apply to the Court to be appointed as lead plaintiff in the lawsuit.Click here to participate in the action.Verrica is a dermatology therapeutics company that develops treatments for people living with skin diseases. Its lead product candidate, VP-102, is a drug-device combination of a topical solution of cantharidin administered through the Company’s single-use precision applicator. The Company is initially developing VP-102 for the treatment of molluscum contagiosum, or molluscum, a highly contagious and primarily pediatric viral skin disease,
Show less
Read more
Impact Snapshot
Event Time:
VRCA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VRCA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VRCA alerts
High impacting Verrica Pharmaceuticals Inc. news events
Weekly update
A roundup of the hottest topics
VRCA
News
- Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $8.00 price target on the stock.MarketBeat
- Strong week for Verrica Pharmaceuticals (NASDAQ:VRCA) shareholders doesn't alleviate pain of three-year loss [Yahoo! Finance]Yahoo! Finance
- Verrica Pharmaceuticals Announces Presentation at the 23rd Annual Needham Virtual Healthcare ConferenceGlobeNewswire
- Verrica Pharmaceuticals Announces that YCANTH™ Receives New Chemical Entity Status and Orange Book Listing from the FDA [Yahoo! Finance]Yahoo! Finance
- Verrica Pharmaceuticals Announces that YCANTH™ Receives New Chemical Entity Status and Orange Book Listing from the FDAGlobeNewswire
VRCA
Earnings
- 2/29/24 - Miss
VRCA
Sec Filings
- 3/19/24 - Form 4
- 3/19/24 - Form 4
- 3/19/24 - Form 4
- VRCA's page on the SEC website